Journal of Cell Science & Therapy
Open Access
ISSN: 2157-7013
+44 1300 500008
ISSN: 2157-7013
+44 1300 500008
Mohamed Awad, Doaa A. Aladle, Nashwa K. Abousamra, Doaa M. Elghannam and Iman m fawzy
Mansoura University, Egypt
Accepted Abstracts: J Cell Sci Ther
Aim: To assess the prognostic role of myeloid transcription factor gene CEBPA (CCAAT/enhancer binding protein-�?±), a novel gene involved in leukemia in Egyptian adults AML. Materials and Methods: Screening for CEBPA mutations was assessed using PCR-single-strand conformation polymorphism (PCR-SSCP) in pretreatment bone marrow samples from 55 newly diagnosed adult AML. Results: CEBPA mutations were found in 11 (20%) of 55 AML patients. They had significantly higher hemoglobin (p=0.037), and lower LDH (p=0.003) levels when compared to those without. CEBPA mutations were frequently detected in M4 (45.5%) and M2 (27.2%) subtypes, and significantly associated with normal karyotype (90.9%, p=0.007). We distinguished 6 cases with 2 different mutations or one homozygous mutation (CEBPA double-mut) as well as 5 cases with only one single heterozygous mutation (CEBPA single-mut). Patients with CEBPA mutations had significantly higher complete remission (p=0.047), lower mortality (p=0.047). Double CEBPA mutant cases showed longer disease free survival (DFS) and overall survival (OS) when compared to wild type CEBPA (for DFS; median=27 versus 24 months respectively; p=0.009 and for OS; median=28 versus 25 months respectively; (p=0.008). No significant differences were found between CEBPA single-mut cases and wild type cases regarding DFS and OS (for DFS; median=13 versus 24 months respectively; p=0.615 and for OS; median=14 versus 25 months respectively; p=0.703). Conclusion: CEBPA mutation status is known to be a prognostic factor for favorable outcome in AML patients. CEBPAdoublemut is associated with favorable DFS and OS. In contrast, CEBPAsingle-mut AMLs survival studies did not differ significantly with wild-type cases. These results demonstrate significant underlying heterogeneity within CEBPA mutation positive AML with prognostic relevance. Based on these findings, we propose that CEBPAdouble-mut should be clearly defined from CEBPAsingle-mut AML and considered as a separate entity in the classification of AML. Furthermore, incorporation of CEBPA mutation status into novel risk-adapted therapeutic strategies in Egypt will improve the currently disappointing cure rate of this group of patients. Mohamed Awad et al., J Cell Sci Ther 2013, 4:4 http://dx.doi.org/10.4172/2157-7013.S1.026
Email: abosamrana@yahoo.com